Related Experiment Video
Updated: Mar 19, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Apixaban to prevent stroke in patients with atrial fibrillation: a review
Benjamin E Peterson1, Sana M Al-Khatib2, Christopher B Granger2
1Duke University Hospital, 2301 Erwin Road, Durham, NC 27710, USA.
Insights
Apixaban is a novel oral anticoagulant that effectively prevents stroke in atrial fibrillation patients. It offers superior stroke prevention compared to warfarin with a reduced risk of major bleeding.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Atrial fibrillation (AF) is a prevalent cardiovascular arrhythmia associated with significant morbidity and healthcare costs.
- Stroke prevention is a critical management goal for patients with atrial fibrillation.
- Novel oral anticoagulants (NOACs) targeting Factor IIa or Xa have transformed AF treatment.
Purpose of the Study:
- To review the efficacy and tolerability of apixaban for stroke prevention in atrial fibrillation.
- To assess the generalizability of apixaban trial findings to broader patient populations.
Main Methods:
- Review of data from the AVERROES and ARISTOTLE clinical trials.
- Analysis of secondary trial data and subgroup findings.
- Evaluation of apixaban's safety and effectiveness profile.
Main Results:
- Apixaban demonstrated superior stroke prevention compared to warfarin in the general AF population.
- Apixaban was associated with a significantly lower risk of major bleeding than warfarin.
- These benefits were observed across various high-risk patient subgroups.
Conclusions:
- Apixaban is a highly effective and safe anticoagulant for stroke prevention in atrial fibrillation.
- Apixaban offers advantages over warfarin in both efficacy and safety, including in high-risk populations.
Abstract:
Atrial fibrillation is a common, costly and morbid cardiovascular arrhythmia. Stroke prevention remains the mainstay of treatment for atrial fibrillation, and the recent advent of novel oral anticoagulants with direct factor IIa or factor Xa inhibition has significantly revolutionized this aspect of treatment for atrial fibrillation patients. This review focuses on the tolerability and efficacy of apixaban and tackles the generalizability of the findings with apixaban to broader patient populations than those primarily enrolled in the clinical trials, drawing from the AVERROES and ARISTOTLE trials and their subsequent secondary analyses. Taken together, findings from these trials show that apixaban is superior to warfarin in preventing stroke with a lower risk of major bleeding in the general population of patients with atrial fibrillation as well as in several key high-risk patient subgroups.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Atherosclerosis III: Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

